Low-density lipoprotein apheresis versus lipid lowering drugs in the treatment of severe hypercholesterolemia: Four years' experience

Artificial Organs

Volumn 20, Issue 4, 1996, Pages 318-323

  Schiel, Ralf ^a   Bambauer, Rolf ^b   Müller, Ulrich ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Coronary heart disease; Hyperlipidemia; LDL apheresis; Lipid lowering drugs

Indexed keywords

CARDIOLOGY; DRUG INTERACTIONS; HEART; LIPOPROTEINS; PATIENT TREATMENT;

CORONARY HEART DISEASE; DOSE-DEPENDENT MANNER; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LDL APHERESIS; LIPID LOWERING; LIPID LOWERING DRUG; LOW DENSITY LIPOPROTEINS; MYOCARDIAL INFARCTION; PATIENT'S SUFFERING;

DISEASES;

ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; GEMFIBROZIL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL;

EID: 0029906274     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb04451.x     Document Type: Article

References (32)

1. Report of the Working Group of Arteriosclerosis of the National Heart, Lung, and Blood Institute. Washington, DC: U.S. Government Printing Office, Department of Health Education and Welfare Publication No. (NIH) 82-2035, 1982.
2. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiovasc 1992;70:733-7.
3. Hjermann I, Holme I, Leven P. Oslo study diet and antismoking trial. Results after 102 months. Am J Med 1986; 80:701-11.
4. Huttunen JK, Manninen V, Mänttäri M, Koskinen P, Romo M, Tenkanen L, Heinonen OP, Frick MH. The Helsinki heart study: central findings and clinical implications. Ann Med 1991;23:155-9.
5. Smith GD, Shipley MJ, Marmot MG, Rose GR. Plasma cholesterol concentration and mortality. The Whithehall study. JAMA 1992;267:70-6.
6. Task Force on Cholesterol Issues, American Heart Association. The cholesterol facts. Special report. Circulation 1990;81(5):1721-33.
7. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1388-9.
8. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-73.
9. Cooke T, Sheahan R, Foley D, Reilly M, D'Arey G, Jauch W, Gibney M, Gearty G, Crean P, Walsh M. Lipoprotein (a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994;89: 1593-8.
10. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339: 303-5.
11. Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp(a) lipoprotein is an independent discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994;154:801-6.
12. Winkelmann HR, Siekmeier R, Kullmer T, Prott M, Schneider W, März W. Genetischer Polymorphisms des Apolipoprolein E-Ein Vergleich zwischen Koronarkranken und Gesunden. Herz/Kreisl 1994;26:194-9.
13. The expert panel: report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
14. Watts GK, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid lowering diet or diet plus cholestyramine in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;229:563-9.
15. Thiery J, Armstrong V, Bosch T, Eisenhauer T, Schuff-Werner P, Seidel D. Maximaltherapie der Hypercholesterinämie bei koronarer Herzerkrankung. Ther Umsch 1990;47: 520-9.
16. Armstrong VW, Schleef J, Thiery J, Muche R, Scuff-Werner P, Eisenhauer T, Seidel D. Effect of HELP-LDL-apheresis on serum concentration of human lipoprotein (a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989;19:235-40.
17. Bambauer R, Keller HE, Latza R, Schiel R. LDL apheresis in hypercholesterolemia with the liposorber system and the immunoadsorption (abstract). Artif Oragans 1994;18:121.
18. Bambauer R, Keller HE, Schiel R. Three year experience with the liposorber system in hypercholesterolemia. In: Agishi T, Kawamura A, Mineshima A. eds. Therapeutic plasmapheresis XII, 1993:415-20.
19. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D, and The HELP-Study Group. The HELP-LDL-apheresis mullicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
20. Agishi T, Wood W, Gordon B. LDL apheresis using the Liposorber® LA-15 system in coronary and peripheral vascular disease associated with severe hypercholesterolemia. Curr Ther Res 1994;55:879-904.
21. Apstein CS, Zilversmith DB, Lees RS, George PK. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis 1978;31:105-15.
22. Rose GA, Blackburn H. Cardiovascular survey methods. WHO Monograph Series 1968;56:137-54.
23. World Health Organization Expert Committee. Second report on diabetes mellitus. World Health Organization Technical Report Series No. 646. Geneva: World Health Organization, 1980.
24. Study Group European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J 1987;8:77-88.
25. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. McGill HC. Persistent problems in the pathogenesis of atherosclerosis. Artherosclerosis 1984;4:443-51.
27. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993;306:1313-8.
28. Blankenhorn DH, Nessim SA, Johnson RL, San Marco ME, Azen SP, Cashen-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257: 3233-40.
29. Galle J, Bassenge E. Influence of low density lipoproteins (LDL) on the reactivity of atherosclerotic arteries. Z Kardiol 1991;80(Suppl 9):15-20.
30. Levine GN, Keancy JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995;332:512-21.
31. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
32. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332: 481-7.